Vycor Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 15, 2022 at 11:07 am EDT
Share
Vycor Medical, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 0.327923 million compared to USD 0.491427 million a year ago. Net loss was USD 0.09901 million compared to USD 0.009374 million a year ago.
For the six months, sales was USD 0.641756 million compared to USD 0.787176 million a year ago. Net loss was USD 0.173562 million compared to USD 0.252293 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Basic loss per share was USD 0.01 compared to USD 0.01 a year ago.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
